Suchergebnisse - "Dejnirattisai, Wanwisa"

PubPharm (116)

41

Tracking the Emergence of SARS-CoV-2 Alpha Variant in the United Kingdom

enthalten in: The New England journal of medicine | 2021

von Walker, A. | Vihta, K. | Gethings, O. | +96

42

Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

enthalten in: bioRxiv.org | 2021

von Dejnirattisai, W. | Huo, J. | Zhou, D. | +68

43

Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

enthalten in: bioRxiv : the preprint server for biology | 2021

von Dejnirattisai, W. | Huo, J. | Zhou, D. | +70

UpdateIn: Cell. 2022 Feb 3;185(3):467-484.e15. - PMID 35081335

44

Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccine

enthalten in: bioRxiv.org | 2021

von Watanabe, Y. | Mendonça, L. | Allen, E. | +20

45

The epitope arrangement on flavivirus particles contributes to Mab C10's extraordinary neutralization breadth across Zika and dengue viruses

enthalten in: Cell | 2021

von Sharma, A. | Zhang, X. | Dejnirattisai, W. | +14

CommentIn: Cell. 2021 Dec 9;184(25):6015-6016. - PMID 34856127

46

Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine

enthalten in: Cell | 2021

von Payne, R. | Longet, S. | Austin, J. | +133

47

Anti-spike antibody response to natural SARS-CoV-2 infection in the general population

enthalten in: Nature communications | 2021

von Wei, J. | Matthews, P. | Stoesser, N. | +78

48

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK : a substudy of two randomised controlled trials (COV001 and COV002)

enthalten in: Lancet (London, England) | 2021

von Flaxman, A. | Marchevsky, N. | Jenkin, D. | +135

CommentIn: Lancet. 2021 Sep 11;398(10304):933-935. - PMID 34480860

49

Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom

enthalten in: Nature microbiology | 2021

von Wei, J. | Stoesser, N. | Matthews, P. | +68

50

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection : a single-arm substudy of a phase 2/3 clinical trial

enthalten in: The lancet. HIV | 2021

von Frater, J. | Ewer, K. | Ogbe, A. | +67

CommentIn: Lancet HIV. 2021 Aug;8(8):e455-e456. - PMID 34153265